The U.S. Food and Drug Administration (FDA) needs to do a better job of warning pregnant women that taking SSRIs, a type of antidepressant, may harm them and their developing baby, doctors told the agency Monday.
The FDA hosted an expert panel of developmental biologists, psychiatrists, epidemiologists, obstetricians and mental health experts who discussed selective serotonin reuptake inhibitors (SSRIs) and pregnancy. The agency livestreamed the two-hour conversation on YouTube and X.
SSRIs have been “implicated in different studies to be involved in postpartum hemorrhage, pulmonary hypertension and cognitive downstream effects in the baby, as well as cardiac birth defects,” said FDA Commissioner Marty Makary, who opened the event.
Nearly 1 in 4 middle-aged women and up to 5% of pregnant women are on an antidepressant, Makary said.
“Antidepressants like SSRIs can be an effective treatment for depression, but we have to stop and also look at the big picture,” he said. “The more antidepressants we prescribe, the more depression there is. … We have to start talking about root causes.”
SSRIs in particular warrant scrutiny as serotonin “may play a crucial role in the development of organs of a baby in utero,” he said.
Hellbound and Down 